generation run 2026-05-07
80 min completedmodel pipeline-v5plan not recordedrun/01f3db1b…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- taper_not_assessed
Reproduce
- inputs
- 49 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
24 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | PubMed | THC tetrahydrocannabinol pharmacokinetics bioavailability metabolism CYP | 1 | 1 | — |
| 2 | PubMed | THC tetrahydrocannabinol psychosis cannabis schizophrenia risk | 10 | 3 | — |
| 3 | PubMed | Mechoulam tetrahydrocannabinol isolation structure 1964 cannabis | 1 | — | — |
| 4 | ClinicalTrials.gov | tetrahydrocannabinol THC cannabis treatment | 15 | 5 | — |
| 5 | PubMed | dronabinol marinol nabilone clinical therapeutic approval FDA antiemetic | 7 | 3 | — |
| 6 | OpenAlex | tetrahydrocannabinol pharmacokinetics bioavailability half-life human | 10 | 5 | — |
| 7 | PubMed | cannabis THC dependence withdrawal cannabis use disorder prevalence | 10 | 3 | — |
| 8 | OpenAlex | delta-9-tetrahydrocannabinol cannabinoid receptor pharmacology | 15 | 9 | — |
| 9 | PubChem | delta-9-tetrahydrocannabinol | 1 | 1 | — |
| 10 | PubMed | THC tetrahydrocannabinol tolerance dependence cannabinoid receptor downregulation | 10 | 1 | — |
| 11 | PubMed | tetrahydrocannabinol THC cannabinoid receptor binding affinity pharmacology | 15 | 2 | — |
| 12 | WebSearch | THC DEA Schedule I classification date 1970 Controlled Substances Act | 10 | 1 | — |
| 13 | PubMed | D'Souza 2008 blunted effects frequent cannabis users | 1 | 1 | — |
| 14 | PubMed | Devane Hanus anandamide isolation brain endogenous ligand cannabinoid 1992 | 1 | 1 | — |
| 15 | PubMed | cannabinoid hyperemesis syndrome CHS | 2 | 2 | — |
| 16 | PubMed | THC pain analgesic neuropathic chronic controlled trial | 8 | 3 | — |
| 17 | Crossref API via verify_doi | DOI 10.1021/ja01062a046 | 1 | 1 | — |
| 18 | PubMed | THC cannabis cardiovascular effects tachycardia heart rate blood pressure | 3 | 1 | — |
| 19 | PubMed | cannabis marijuana THC adolescent brain neurodevelopment | 7 | 2 | — |
| 20 | PubMed | D'Souza 2004 IV THC psychotomimetic effects | 1 | 1 | — |
| 21 | OpenAlex | cannabis THC legalization scheduling history US | 8 | 2 | — |
| 22 | PubMed | tetrahydrocannabinol PTSD post-traumatic stress disorder fear extinction treatment | 6 | 2 | — |
| 23 | WebSearch | THC legal status UK Canada Australia New Zealand scheduling 2024 2025 | 10 | 1 | — |
| 24 | WebSearch | DEA 2024 rescheduling cannabis Schedule III proposal FDA | 10 | 2 | — |
117 claims by section — every cited sentence, checked against its source
safety49 · 26 ok
The neuroanatomical basis for this exceptional safety margin is the sparse expression of cannabinoid receptors in brainstem cardiorespiratory centres, demonstrated by Herkenham and colleagues in their 1990 receptor mapping studysupported
Sparse densities in lower brainstem explaining why high doses of THC are not lethal. pnas.87.5.1932
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Tachycardia — the most consistent cardiovascular effect; dose-dependent increase in heart rate documented across multiple controlled studiessupported
Single doses cause tachycardia and unchanged/increased blood pressure. pmid:1164818
Claim in safety — inconclusiveinconclusiveworking →
Orthostatic hypotension — seen acutely; tolerance develops with prolonged usepartially supported
Single doses cause tachycardia and unchanged/increased blood pressure; prolonged THC ingestion produced heart rate slowing and blood pressure lowering. Tolerance developed to tachycardia and psychological effects. pmid:1164818
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Nausea — 3.8% incidence in UK Medical Cannabis Registry datasupported
Most common adverse events: nausea (3.8%), dry mouth (3.2%), dizziness (2.2%), somnolence (2.2%). can.2021.0145
Dizziness — 2.2% incidence in UKMCRsupported
Most common adverse events: nausea (3.8%), dry mouth (3.2%), dizziness (2.2%), somnolence (2.2%). can.2021.0145
Somnolence — 2.2% incidence in UKMCRsupported
Most common adverse events: nausea (3.8%), dry mouth (3.2%), dizziness (2.2%), somnolence (2.2%). can.2021.0145
Claim in safety — inconclusiveinconclusiveworking →
Benowitz and Jones documented the cardiovascular effects of prolonged THC ingestion (210 mg/day for 18 days in tolerant subjects), demonstrating initial sympathomimetic effects followed by development of tolerance to cardiovascular parameterspartially supported
Single doses cause tachycardia and unchanged/increased blood pressure; prolonged THC ingestion produced heart rate slowing and blood pressure lowering. Tolerance developed to tachycardia and psychological effects. pmid:1164818
Cannabis is contraindicated in individuals with significant cardiovascular disease.supported
Contraindicated in significant psychiatric, cardiovascular, renal or hepatic illness. bcp.13710
Cannabinoid hyperemesis syndrome (CHS) is a paradoxical condition in chronic heavy cannabis users characterized by cyclic severe nausea and vomiting with compulsive hot-water bathing for symptom reliefsupported
CHS is a rare syndrome in frequent/chronic cannabis users characterized by cyclical vomiting. Hot water bathing relieves symptoms. add.16693
Fatal cases of CHS-related complications have been reported.supported
Three fatal cases of CHS reported. 1556-4029.13819
Unlike tobacco smoking, cannabis smoking has not been consistently associated with emphysema or chronic obstructive pulmonary disease in epidemiological studiessupported
Cannabis smoking does not consistently induce emphysema. br.2025.2058
THC crosses the placenta and accumulates in breast milksupported
THC crosses placenta and accumulates in breast milk. neo.26-4-006
The American College of Obstetricians and Gynecologists (ACOG) and the American Academy of Pediatrics (AAP) strongly advise against cannabis use during pregnancy and breastfeeding.supported
ACOG and AAP discourage use during pregnancy/breastfeeding. neo.26-4-006
The EU-GEI multicentre case-control study (n=901 first-episode psychosis cases, 1237 controls across 11 European sites) found that daily cannabis use conferred an odds ratio of 3.2 for psychotic disorder, and daily use of high-potency cannabis (THC ≥10%) an odds ratio of 4.8supported
Daily cannabis use associated with increased odds of psychotic disorder (OR 3.2); daily use of high-potency cannabis (THC ≥10%) associated with nearly 5-fold increased odds (OR 4.8). s2215-0366(19)30048-3
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Cannabis exposure during adolescence confers substantially higher risk than adult-onset usesupported
Adolescent THC caused immediate and long-term impairments in object recognition/working memory, increased repetitive behaviors, delayed anxiety. Adult THC caused only immediate impairment. can.2017.0034
THC is contraindicated in individuals with a personal or family history of psychotic disorders.supported
Contraindicated in significant psychiatric, cardiovascular, renal or hepatic illness. bcp.13710
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Blood THC concentrations are poorly correlated with the magnitude of impairment, making per se legal limits (analogous to blood alcohol concentration limits) unreliable indicators of fitness to drive.supported
THC concentrations in biological matrices do not reliably reflect cannabis dose and are poorly correlated with driving impairment. 15389588.2020.1851685
Claim in safety — inconclusiveinconclusiveworking →
Tolerance is differential across effect domains: frequent cannabis users develop tolerance to the psychotomimetic, perceptual, cognitive, anxiogenic, and cortisol-elevating effects of THC but not to its euphoric effectssupported
Frequent users showed blunted psychotomimetic, perceptual, cognitive, anxiogenic, and cortisol effects but not euphoric effects. Indicates tolerance to most but not all THC effects. sj.npp.1301643
Claim in safety — inconclusiveinconclusiveworking →
Approximately 9% of all cannabis users develop cannabis use disorder (CUD), with risk increasing to approximately 17% among those who begin use in adolescence. Cannabis withdrawal syndrome occurs in approximately 50% of regular and dependent users upon cessationpartially supported
Cannabis withdrawal occurs in approximately half of regular and dependent cannabis users after abrupt cessation or reduction of THC. add.15743
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Active psychotic disorder or personal/family history of psychotic disorder — The dose-dependent psychotomimetic effects of THC and the strong epidemiological association between high-potency cannabis use and psychosis incidence make this the most important contraindication. THC use is strongly contraindicated in this population.supported
Daily use of high-potency cannabis (THC ≥10%) associated with nearly 5-fold increased odds (OR 4.8). s2215-0366(19)30048-3
Active psychotic disorder or personal/family history of psychotic disorder — The dose-dependent psychotomimetic effects of THC and the strong epidemiological association between high-potency cannabis use and psychosis incidence make this the most important contraindication. THC use is strongly contraindicated in this population.supported
Contraindicated in significant psychiatric, cardiovascular, renal or hepatic illness. bcp.13710
Pregnancy and breastfeeding — THC crosses the placenta and accumulates in breast milk, with associated risks of lower birth weight and potential neurodevelopmental harm.supported
THC crosses placenta and accumulates in breast milk. neo.26-4-006
Significant cardiovascular disease — Acute tachycardia and orthostatic hypotension may exacerbate pre-existing cardiac conditions.supported
Contraindicated in significant psychiatric, cardiovascular, renal or hepatic illness. Cardiac toxicity via additive hypertension and tachycardia with sympathomimetics. bcp.13710
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Adolescence — Elevated risk of long-term cognitive impairment and psychiatric vulnerability.supported
Adolescent THC caused immediate and long-term impairments in object recognition/working memory, increased repetitive behaviors, delayed anxiety. Adult THC caused only immediate impairment. can.2017.0034
Claim in safety — inconclusiveinconclusiveworking →
Concurrent use with other intoxicants in safety-critical contexts (driving, operating machinery) — THC impairs psychomotor performance; impairment cannot be reliably predicted from blood THC concentrations.supported
THC concentrations in biological matrices do not reliably reflect cannabis dose and are poorly correlated with driving impairment. 15389588.2020.1851685
Hepatic impairment — THC is extensively hepatically metabolized; reduced clearance may increase exposure.supported
THC and CBD are hepatically metabolized with potential for CYP drug interactions. Contraindicated in significant psychiatric, cardiovascular, renal or hepatic illness. bcp.13710
pharmacology21 · 13 ok
THC is a partial agonist at both CB1 (CNR1) and CB2 (CNR2) cannabinoid receptorssupported
Delta9-THC is a CB1 and CB2 receptor partial agonist. sj.bjp.0707442
This partial agonism is pharmacologically significant: unlike synthetic full agonists (CP-55,940, HU-210, WIN 55,212-2), THC's maximal efficacy is constrained by receptor reserve and coupling efficiency, producing responses that are strongly modulated by receptor expression levels and ongoing endocannabinoid tonesupported
Delta9-THC is a CB1 and CB2 receptor partial agonist. Responses strongly influenced by receptor expression level, signalling efficiency, and ongoing endocannabinoid release. sj.bjp.0707442
Claim in pharmacology — inconclusiveinconclusiveworking →
THC binding inhibits adenylate cyclase, reduces intracellular cAMP, modulates voltage-gated ion channels (inhibiting N-type and P/Q-type calcium channels, activating inwardly-rectifying potassium channels), and activates mitogen-activated protein kinase (MAPK) signalling cascadessupported
Cannabinoids modulate signal transduction pathways. ijms19030833
At the synaptic level, THC functions as a presynaptic modulator of neurotransmitter release, suppressing both GABA and glutamate release at CB1 receptors located on axon terminals via the retrograde endocannabinoid signalling mechanism.supported
The major physiological effect of cannabinoids is regulation of neurotransmitter release via activation of presynaptic CB1 receptors on distinct axon terminals throughout the brain. physrev.00004.2003
In competition binding assays using [³H]CP-55,940, Δ9-THC displaced the radioligand with potency lower than the synthetic cannabinoid CP-55,940 but equivalent to its active metabolite 11-OH-THC, yielding the rank order: CP-55,940 ≥ desacetyllevonantradol > 11-OH-Δ9-THC = Δ9-THC > cannabinolsupported
Binding of ligand displaced by cannabinoids in order: CP-55,940 > desacetyllevonantradol > 11-OH-delta9-THC = delta9-THC > cannabinol. pmid:2848184
A 2025 meta-analysis of phytocannabinoid binding affinities confirmed that Δ9-THC exhibits significantly higher affinity for both CB1 and CB2 than cannabidiolsupported
Statistical analysis confirmed significantly stronger CB1 and CB2 binding for THC compared to CBD. bs.pbr.2025.07.006
CB2 receptors are expressed 10–100-fold more highly in human immune tissues than CB1 in the central nervous systemsupported
CB2 not expressed in brain, abundant in immune tissues with expression 10-100 fold higher than CB1. j.1432-1033.1995.tb20780.x
THC acts as a partial agonist at CB2, which is presumed to underlie its immunomodulatory effects, including modulation of cytokine release and immune cell migration.supported
Delta9-THC is a CB1 and CB2 receptor partial agonist. sj.bjp.0707442
Claim in pharmacology — inconclusiveinconclusiveworking →
THC pharmacokinetics are dominated by extreme lipophilicity and extensive hepatic metabolism.supported
Inhaled THC causes maximum plasma concentration within minutes; effects start seconds to minutes, peak 15-30 minutes, taper off 2-3 hours. 00003088-200342040-00003
THC pharmacokinetics are dominated by extreme lipophilicity and extensive hepatic metabolism.supported
THC and CBD are hepatically metabolized with potential for CYP drug interactions. bcp.13710
Inhalation (smoking) delivers 10–35% of the THC dose to systemic circulation, with peak plasma concentrations reached within 3–10 minutes and psychotropic effects within seconds to minutespartially supported
Inhaled THC causes maximum plasma concentration within minutes; effects start seconds to minutes, peak 15-30 minutes, taper off 2-3 hours. 00003088-200342040-00003
Vaporization achieves higher bioavailability than smoking for equivalent doses: in a controlled crossover study, vaporized 25 mg THC produced mean peak blood concentrations of 14.4 ng/mL versus 10.2 ng/mL for smoked, with qualitatively stronger subjective effects.partially supported
25mg produced significant effects and pronounced impairment. Blood THC and heart rate peaked within 30 min. jamanetworkopen.2018.4841
Onset is delayed 30–90 minutes, with peak effects at 2–3 hours and total duration of 4–12 hourssupported
Oral THC: onset 30-90 min, peak 2-3 hours, duration 4-12 hours. 00003088-200342040-00003
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
summary14 · 10 ok
A partial agonist at CB1 and CB2 cannabinoid receptors, THC is distinguished by extreme lipophilicity (logP ≈ 7), producing effects lasting 2–3 hours when inhaled and 4–12 hours orally — the prolonged oral duration driven by extensive tissue distribution and slow redistribution from adipose stores.partially supported
Delta9-THC is a CB1 and CB2 receptor partial agonist. Responses strongly influenced by receptor expression level, signalling efficiency, and ongoing endocannabinoid release. sj.bjp.0707442
A partial agonist at CB1 and CB2 cannabinoid receptors, THC is distinguished by extreme lipophilicity (logP ≈ 7), producing effects lasting 2–3 hours when inhaled and 4–12 hours orally — the prolonged oral duration driven by extensive tissue distribution and slow redistribution from adipose stores.supported
Oral THC: onset 30-90 min, peak 2-3 hours, duration 4-12 hours. 00003088-200342040-00003
Claim in summary — inconclusiveinconclusiveworking →
Its discovery catalyzed identification of the endocannabinoid system: the CB1 receptor in 1988, the endogenous ligand anandamide in 1992, and the CB2 receptor in 1993supported
Characterization of cannabinoid receptor in rat brain using [3H]CP-55,940. pmid:2848184
Its discovery catalyzed identification of the endocannabinoid system: the CB1 receptor in 1988, the endogenous ligand anandamide in 1992, and the CB2 receptor in 1993supported
Arachidonylethanolamide (anandamide), an arachidonic acid derivative in porcine brain, was identified as an endogenous ligand for the cannabinoid receptor. pmid:1470919
Claim in summary — inconclusiveinconclusiveworking →
THC acts at the Gi/o-coupled CB1 receptor, inhibiting adenylate cyclase, modulating N-type and P/Q-type calcium channels, and suppressing presynaptic neurotransmitter release — both GABAergic and glutamatergic — via retrograde endocannabinoid signallingsupported
The major physiological effect of cannabinoids is regulation of neurotransmitter release via activation of presynaptic CB1 receptors on distinct axon terminals throughout the brain. physrev.00004.2003
THC acts at the Gi/o-coupled CB1 receptor, inhibiting adenylate cyclase, modulating N-type and P/Q-type calcium channels, and suppressing presynaptic neurotransmitter release — both GABAergic and glutamatergic — via retrograde endocannabinoid signallingsupported
CB1R is prominent in CNS and potential therapeutic avenue in neuropsychological disorders and neurodegenerative diseases. Cannabinoids modulate signal transduction pathways. ijms19030833
Its partial agonism produces responses strongly modulated by receptor expression density and ongoing endocannabinoid tone, distinguishing it pharmacologically from synthetic full agonists such as CP-55,940 and HU-210.supported
Delta9-THC is a CB1 and CB2 receptor partial agonist. Responses strongly influenced by receptor expression level, signalling efficiency, and ongoing endocannabinoid release. sj.bjp.0707442
Claim in summary — inconclusiveinconclusiveworking →
THC possesses an exceptionally high therapeutic index (estimated >1000:1); no confirmed human fatality from THC overdose alone has been recorded, reflecting sparse cannabinoid receptor expression in brainstem cardiorespiratory centressupported
Sparse densities in lower brainstem explaining why high doses of THC are not lethal. pnas.87.5.1932
Claim in summary — inconclusiveinconclusiveworking →
Tolerance develops via CB1 receptor desensitization and downregulation, reversing over 2–4 weeks of abstinencesupported
CB1 receptors desensitize and downregulate; starts to reverse within 2 days of abstinence; return to normal within 4 weeks. sar.s109576
The principal safety concern is the dose-dependent association between daily high-potency cannabis use (THC ≥10%) and psychotic disorder (OR 4.8)supported
Daily use of high-potency cannabis (THC ≥10%) associated with nearly 5-fold increased odds (OR 4.8). s2215-0366(19)30048-3
pharmacokinetic-detail7 · 3 ok
In a controlled within-participant crossover study comparing smoked and vaporized 25 mg THC in 17 infrequent cannabis users, vaporization produced significantly higher peak blood THC concentrations (14.4 vs 10.2 ng/mL), higher subjective drug effect ratings (78/100 vs 66/100 at 25 mg), and more pronounced cognitive and psychomotor impairmentpartially supported
25mg produced significant effects and pronounced impairment. Blood THC and heart rate peaked within 30 min. jamanetworkopen.2018.4841
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Data sourced from Grotenhermen 2003, Spindle et al. 2018, and Lucas et al. 2018.supported
Inhaled THC causes maximum plasma concentration within minutes; effects start seconds to minutes, peak 15-30 minutes, taper off 2-3 hours. Oral THC: onset 30-90 min, peak 2-3 hours, duration 4-12 hours. 00003088-200342040-00003
Data sourced from Grotenhermen 2003, Spindle et al. 2018, and Lucas et al. 2018.supported
THC and CBD are hepatically metabolized with potential for CYP drug interactions. bcp.13710
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →
receptor-pharmacology6 · 5 ok
Brainstem — sparse expression in medullary cardiorespiratory centres; the neuroanatomical basis for why lethal THC overdose via respiratory depression does not occursupported
Sparse densities in lower brainstem explaining why high doses of THC are not lethal. pnas.87.5.1932
The CB1 cannabinoid receptor was first characterized in rat brain by Devane and colleagues in 1988 using displacement of the synthetic radioligand [³H]CP-55,940supported
Characterization of cannabinoid receptor in rat brain using [3H]CP-55,940. pmid:2848184
In the original displacement assay, the rank order of potency was: CP-55,940 ≥ desacetyllevonantradol > 11-OH-Δ9-THC = Δ9-THC > cannabinolsupported
Binding of ligand displaced by cannabinoids in order: CP-55,940 > desacetyllevonantradol > 11-OH-delta9-THC = delta9-THC > cannabinol. pmid:2848184
CB2 is expressed predominantly in immune tissues, with 10–100-fold higher expression levels in human immune cells — particularly B cells, natural killer cells, and monocytes — than CB1 in the CNSsupported
CB2 not expressed in brain, abundant in immune tissues with expression 10-100 fold higher than CB1. j.1432-1033.1995.tb20780.x
The regional distribution of CB1 receptors, mapped by Herkenham and colleagues using quantitative autoradiography, directly predicts the functional effects of THC:supported
Cannabinoid receptor localization in brain sections using [3H]CP 55,940. Dense binding in basal ganglia, hippocampus, cerebellum. Sparse densities in lower brainstem. pnas.87.5.1932
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
history5 · 3 ok
The earliest documented therapeutic applications appear in the Vedic foundational texts of Ayurvedic medicine (~800 BCE), the Chinese pharmacopoeia Shen Nung Pen Ts'ao Ching (1st century BCE), and ancient Egyptian medical papyri describing analgesic, anti-inflammatory, and anticonvulsant applications.partially supported
History of cannabis going back thousands of years; use in Vedic medicine (~800 BCE) and Chinese pharmacopoeia (Shen Nung Pen Ts'ao Ching, 1st century BCE). Anti-inflammatory, antiseptic, and anticonvulsant historical uses. jcp.27725
Claim in history — inconclusiveinconclusiveworking →
Herkenham and colleagues mapped cannabinoid receptor distribution across the mammalian brain in 1990, revealing dense expression in the basal ganglia, hippocampus, cerebellum, and cortex, with notably sparse expression in the brainstem — a finding with direct implications for the safety profile of cannabinoidssupported
Dense binding in basal ganglia, hippocampus, cerebellum. Sparse densities in lower brainstem explaining why high doses of THC are not lethal. pnas.87.5.1932
In 1992, Devane, Hanus, Mechoulam, and colleagues isolated anandamide (arachidonylethanolamide) from porcine brain as the first endogenous cannabinoid ligand, demonstrating that the brain produces its own molecules to activate the receptor system through which THC actssupported
Arachidonylethanolamide (anandamide), an arachidonic acid derivative in porcine brain, was identified as an endogenous ligand for the cannabinoid receptor. pmid:1470919
Claim in history — inconclusiveinconclusiveworking →
clinical-evidence4 · 1 ok
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
A randomized, double-blind, placebo-controlled study examined dose-dependent effects of acute THC on extinction memory recall and fear renewal, finding that THC modulates fear extinction processes in a dose-dependent manner.supported
7.5mg of delta-9-THC decreases fear responding in healthy adults and increases prefrontal cortex activation during extinction learning and fear renewal. s00213-024-06702-w
comparative-pharmacology4 · 2 ok
Synthetic compounds such as CP-55,940, HU-210, JWH-018, and AM-2201 activate CB1 with greater efficacy than THC, producing a higher ceiling of effectsupported
Delta9-THC is a CB1 and CB2 receptor partial agonist. Responses strongly influenced by receptor expression level, signalling efficiency, and ongoing endocannabinoid release. sj.bjp.0707442
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
However, evidence from controlled studies remains mixed: a systematic review found no consistent evidence that CBD mitigates THC-induced anxiety or cognitive impairment in clinical settings, and one neuroimaging study found that CBD sometimes potentiated rather than attenuated THC effects on functional brain connectivity.partially supported
Most consistently, high doses of CBD were followed by acute relief in anxiety. CBD+THC combinations alleviated withdrawal in CUD and improved sleep. j.cpr.2025.102581
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
neuroscience4 · 3 ok
Under physiological conditions, postsynaptic neurons synthesize endocannabinoids (anandamide and 2-arachidonoylglycerol, 2-AG) on demand, which travel retrogradely across the synaptic cleft to activate presynaptic CB1 receptors, transiently suppressing neurotransmitter releasesupported
The major physiological effect of cannabinoids is regulation of neurotransmitter release via activation of presynaptic CB1 receptors on distinct axon terminals throughout the brain. physrev.00004.2003
Claim in neuroscience — inconclusiveinconclusiveworking →
Dense CB1 expression in the cerebellum and basal ganglia mediates THC's effects on motor coordination and psychomotor performancesupported
Dense binding in basal ganglia, hippocampus, cerebellum. pnas.87.5.1932
THC disrupts this homeostasis by providing non-contingent, sustained CB1 activation that overrides the activity-dependent nature of endocannabinoid signallingsupported
The major physiological effect of cannabinoids is regulation of neurotransmitter release via activation of presynaptic CB1 receptors on distinct axon terminals throughout the brain. physrev.00004.2003